Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will participate in two healthcare conferences in February 2026 with senior management presentations and webcasts available.
On Feb 12, 2026 at 2:30 PM EST CEO Dr. Neal Walker will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit. On Feb 26, 2026 at 8:40 AM EST President COO Hugh Davis will present at Oppenheimer 36th Annual Healthcare Life Sciences Conference. Webcasts will be available on the company website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ACRS
In the Feb 4 session, ACRS gained 2.02%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Preclinical data update | Positive | +1.3% | ATI-2138 showed rapid, sustained hair regrowth in murine alopecia model. |
| Jan 12 | Trial initiation | Positive | +0.8% | Initiated Phase 1b proof-of-concept trial in atopic dermatitis for ATI-052. |
| Jan 06 | Clinical results | Positive | +0.0% | Positive interim Phase 1a ATI-052 results with favorable safety and robust PD. |
| Dec 19 | Index inclusion | Positive | -2.2% | Added to Nasdaq Biotechnology Index effective close on December 19, 2025. |
| Nov 25 | Conference participation | Neutral | -0.7% | Announced participation in Piper Sandler healthcare conference with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive R&D and index-inclusion news has produced modest and sometimes mixed 1-day price reactions.
Over the last few months, Aclaris reported several R&D updates and index-related milestones. On Nov 25, 2025, participation in a healthcare conference saw a small negative reaction. Index inclusion in the Nasdaq Biotechnology Index on Dec 19, 2025 was followed by a -2.23% move. In early 2026, positive clinical and preclinical updates for ATI-052 and ATI-2138 generated only modest gains, suggesting tempered expectations despite advancing programs. Today’s conference participation fits this pattern of incremental corporate visibility news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in February 2026.
- On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.
- On Thursday February 26, 2026, at 8:40 AM EST, Aclaris’ President and Chief Operating Officer Hugh Davis, Ph.D. will provide a corporate presentation during the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference.
A live and archived webcast of both events will be accessible on the Events page of https://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
